Investcorp Buys Mercury

Investcorp buys Mercury.
   
Alternative-assets manager Investcorp buys placement agent and advisory firm Mercury Capital Advisors Group.
   
Mercury has broad experience providing advisory services on direct deals and co-investments, joint ventures, and secondary transactions, as well as consulting for general partners.
   
Mohammed Alardhi of Investcorp said: ‘Our partnership with Mercury is in line with Investcorp’s long-term strategy and our mission to serve investors worldwide with an array of attractive opportunities in alternative investments. Mercury is well positioned to deliver unique solutions to clients across the globe through its traditional placement capabilities.’
   
Michael Ricciardi of Mercury said: ‘This partnership is a powerful endorsement of Mercury’s unrelenting commitment both to excellence and to our clients. We have known the Investcorp team for years and believe they are the right partners with whom we can expand our capabilities. We are excited about what this partnership means for Mercury’s outsourced CIO platform and partnerships with other asset managers and family offices.’ 
   
Alan Pardee and Enrique Cuan of Mercury added: ‘We are delighted to be partnering with Investcorp while continuing to keep our independence and ability to work with the world’s leading investors and allocators. We look forward to working with Investcorp’s businesses that partner with third-party managers through seeding and acquisition of minority stakes as a fascinating enhancement to our already strong, independent global placement agency activities.’
   
Freeman & Co. served as financial adviser to Mercury. Clifford Chance US served as legal adviser. 
   
Gibson, Dunn & Crutcher served as legal adviser to Investcorp.

Comments

Post a Comment

Popular posts from this blog

Pepsi Buys Rockstar

Pepsi buys Rockstar .     P epsiCo buys Rockstar Energy Beverages for $3.85 billion.     Founded in 2001, Rockstar is drinks designed for people leading an active lifestyle. Available in 20 flavors at convenience and grocery stores in 30 countries. Distributed by PepsiCo in North America since 2009. Supporting the Rockstar lifestyle across the globe through action sports, motorsports, and live music. Pepsi's energy portfolio also includes Kickstart , GameFuel, and Amp Energy.     The deal reflects the shift from reliance on sales of sugary, fizzy drinks toward options ranging from tea and coffee to still and sparkling water varieties, which appeal to health-conscious and younger consumers. Neither PepsiCo nor Coca-Cola owns a major brand in the energy drinks category, which is forecast to grow to more than $80 billion over the next five years and is now dominated by Red Bull.     2 00 countries and territories around the world enjoy ...
Read more

Compass Buys Marucci

Compass buys Marucci.     Compass Diversified Holdings buys Marucci Sports for $200 million.     Marucci Sports was founded in 2009 by Kurt Ainsworth, a retired pitcher for the San Francisco Giants and Baltimore Orioles, Joe Lawrence, a former second baseman for the Toronto Blue Jays, and Reed Dickens, a former White House Assistant Press Secretary under George W. Bush.     Marucci ’s first buy was Marucci Bat Company, launched out of a backyard shed in 2004. Ainsworth then led the buyout of an Amish-run Pennsylvania wood mill in 2008. This solidified Marucci's superior wood supply, and it still supplies all Marucci's wood today. In 2017 Marucci bought Victus , a baseball equipment maker known for its edgy designs and big attitude.     With vertically cohesive wood bat production, a global supplier group, and a client base of MVPs and World Series winners, Marucci and Victus are the top two bats among Big League players. T...
Read more

Gilead Buys Forty Seven

Gilead buys Forty Seven.     Gilead Sciences buys Forty Seven for $4.9 billion.     Forty Seven is a clinical-stage immuno-oncology firm developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on tech licensed from Stanford. Forty Seven’s lead program, magrolimab , is a monoclonal antibody against the CD47 receptor, a ‘don’t eat me’ signal that cancer cells commandeer to avoid being ingested by macrophages. Evaluated ant ibodies are in many clinical studies of patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. These assets complement the cell therapy franchise Gilead added with its 2017 buy of Kite Pharma .     Beyond magrolimab , Forty Seven is fixing to advance two more compounds into clinical testing. Developing FSI-174, an anti-cKIT antibody, in combination with magrolimab creates a novel, all-antibody conditioning regimen to address ...
Read more